NGLY1 and melanoma: Our results strongly support that NGLY1 suppression in melanoma cells elicits multifaceted cancer-elimination responses, and that targeting NGLY1 and protein deglycosylation may represent a novel anticancer strategy with the opportunity for a broad therapeutic window.